Psychiatry – Page 2

Coenzyme Q10 in Depression and Anxiety: Evaluating Therapeutic Potential Through Meta-Analysis

By MedXY 10/12/2025

This meta-analysis examines Coenzyme Q10 supplementation's impact on depression and anxiety, revealing modest benefits for depression at low doses and short durations but insufficient evidence for anxiety improvement.

Neurology news Psychiatry

Brexpiprazole in Alzheimer’s Disease-Related Agitation: Modest Gains Amidst Safety Uncertainties

By MedXY 10/12/2025

This review evaluates brexpiprazole's efficacy and safety for agitation in Alzheimer's disease, revealing modest symptom improvement but uncertain safety profiles, underscoring the need for individualized therapy and further research.

Emergency Medicine news Psychiatry

Which Mental-Health Steps Should Trauma Teams Prioritize? A Practical Synthesis of New Guideline Recommendations

By MedXY 10/10/2025

A systematic synthesis of clinical practice guideline recommendations for preventing and managing mental disorders after traumatic injury, with prioritized, implementable actions for acute and early recovery care.

Emergency Medicine Pediatrics Psychiatry Radiology

Delays in Pediatric Cannabis Toxicology Testing Lead to Increased Neuroimaging in Emergency Departments

By MedXY 10/09/2025

Delayed cannabis test results in children under 6 with poisoning symptoms prolong ED visits and influence neuroimaging use. Faster toxicology screening could optimize care and reduce unnecessary scans.

Psychiatry Specialties

Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A Four-Year Randomized Clinical Trial Review

By MedXY 10/06/2025

This review synthesizes evidence from a large randomized trial comparing early antipsychotic dose reduction/discontinuation versus maintenance after first-episode psychosis remission, emphasizing short-term risks and long-term functional gains.

Clinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

By MedXY 10/01/2025

A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.

Clinical Updates news Psychiatry Specialties

Heart Rate Variability Biofeedback in Substance Use Disorder: Emerging Evidence from a Randomized Clinical Trial and Contextual Review

By MedXY 10/01/2025

Second-generation heart rate variability biofeedback (HRVB) shows promise in reducing craving, negative affect, and substance use in adults with substance use disorder (SUD), supporting its potential as an adjunctive treatment in early recovery.

Neurology Pediatrics Psychiatry Specialties

Unraveling ADHD: Gut Microbial Signatures and the Role of SCFA Deficiency in Symptom Pathogenesis

By MedXY 09/29/2025

Recent research reveals distinct gut microbial and metabolic profiles linked to ADHD symptoms, highlighting short-chain fatty acid deficiency as a key mechanism driving hyperactivity and inattention.

Medical News Pediatrics Psychiatry Specialties

Restoring Cognitive Function After Adolescent Alcohol Exposure: The Promise of Synbiotic Therapy Targeting the Microbiota-Gut-Brain Axis

By MedXY 09/29/2025

A synbiotic intervention reverses alcohol-induced cognitive deficits in adolescent mice by modulating gut microbiota and brain metabolism, suggesting potential therapeutic avenues for alcohol-related neurobehavioral impairments.

Family Medicine & Nutrition Psychiatry Specialties

Soft Drink Consumption and Depression: The Gut Microbiome Connection, Especially Eggerthella

By MedXY 09/28/2025

This analysis explores how soft drink consumption correlates with major depressive disorder (MDD), revealing gut microbiome alterations—particularly in Eggerthella abundance—that may mediate this association, highlighting potential intervention targets.

news Psychiatry

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY 09/25/2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Clinical Updates news Pediatrics Psychiatry Specialties

Childhood Loneliness: A Lasting Risk Factor for Cognitive Decline and Dementia in Later Life

By MedXY 09/24/2025

Childhood loneliness significantly increases the risk of cognitive decline and dementia in middle-aged and older adults, independent of adult loneliness, highlighting the importance of early psychosocial interventions.

news Pediatrics Psychiatry Specialties

Brain Connectome Modulates the Impact of Adverse Childhood Experiences on Mental Health in Preadolescents

By MedXY 09/23/2025

This cohort study reveals that whole-brain functional connectivity alters the link between adverse childhood experiences and psychiatric disorders in children, particularly for threat-related exposures and females, suggesting a neurobiological basis of resilience in youth.

Medical News news Psychiatry Specialties

Linking Alcohol Consumption Per Capita to Suicide Mortality: Insights from a Meta-Analysis

By MedXY 09/23/2025

A meta-analysis found a population-level association between increased per capita alcohol consumption and higher suicide mortality, without sex differences, suggesting alcohol reduction as a vital component in suicide prevention.

Clinical Updates Psychiatry Public Health Specialties

Unveiling the Burden and Trajectories of Perinatal Anxiety and Depression in a Major Urban Medical Center

By MedXY 09/23/2025

A retrospective study identifies critical gaps in screening and treatment of perinatal anxiety and depression, revealing prevalence rates, symptom trajectories, and the impact of mental health services in 3051 women.

Clinical Updates news Psychiatry

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

By MedXY 09/23/2025

A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option with potentially fewer adverse effects.

Clinical Updates news Psychiatry

Evaluating the Patient Health Questionnaire-15 and Somatic Symptom Scale-8: Insights from a Systematic Review and Meta-Analysis

By MedXY 09/23/2025

This article critically reviews measurement properties of the PHQ-15 and SSS-8, two key instruments assessing somatic symptom burden, highlighting reliability, validity, and clinical applicability based on meta-analyzed evidence from over 300 studies.

Clinical Updates news Psychiatry

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence

By MedXY 09/21/2025

This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonstrating safety and modest efficacy.

Clinical Updates Family Medicine & Nutrition news Psychiatry Specialties

Add-on Probiotics for Inflammatory Depression: Insights from a Double-Blind Randomized Placebo-Controlled Trial

By MedXY 09/17/2025

This study evaluated the antidepressant effects of a Lactobacillus probiotic in overweight depressed patients with systemic low-grade inflammation, revealing no overall benefit but highlighting fecal formic acid as a potential biomarker for treatment response.

Clinical Updates Family Medicine & Nutrition news Psychiatry Specialties

Enhancing Vagal Nerve Function with Multi-Species Probiotics: A Promising Therapeutic Avenue for Major Depression

By MedXY 09/17/2025

A 3-month RCT demonstrates that multi-species probiotic supplementation improves vagal nerve function, gut microbiome composition, and sleep quality in patients with major depression, suggesting novel gut-brain axis interventions.